Both benzimidazole D- and L-ribonucleosides are potent inhibitors of human cytomegalovirus (HCMV) replication. The D-nucleosides TCRB and BDCRB [2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole and its 2-bromo analog] were previously shown to inhibit HCMV DNA cleavage and processing. Mutations identified in genes UL56 and UL89 which encode a putative HCMV terminase were responsible for this resistance. Two strains with mutations either in UL89 or in both UL89 and UL56, also had a mutation (L21F) in gene UL104. This open reading frame encodes a putative HCMV portal protein that interacts with HCMV terminase. To determine if UL104 was involved in drug action, a recombinant virus with the L21F mutation only was constructed using the geno...